Tenax Therapeutics, Inc.
TENX· Nasdaq
TENXTenax Therapeutics, Inc.
Filed Nov 10, 2022 · 10-Q · 41 days after period end · 0001654954-22-015030
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Net Income | $2.92M | $3.80M | -$2.22M | $2.22M |
| EPS Diluted | — | -$0.15 | -$0.18 | -$0.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end
